Healthcare Services
Valuation | |
|---|---|
| Market Cap | 69.14 kCr |
| Price/Earnings (Trailing) | 71.99 |
| Price/Sales (Trailing) | 7.82 |
| EV/EBITDA | 36.28 |
| Price/Free Cashflow | 143.04 |
| MarketCap/EBT | 54.72 |
| Enterprise Value | 72.23 kCr |
Fundamentals | |
|---|---|
Growth & Returns | |
|---|---|
| Price Change 1W | 2.7% |
| Price Change 1M | 2.1% |
| Price Change 6M | -5% |
| Price Change 1Y | 51.6% |
| 3Y Cumulative Return | 50.5% |
| 5Y Cumulative Return | 41.7% |
| 7Y Cumulative Return | 31.5% |
| 10Y Cumulative Return | 18% |
| Revenue (TTM) |
| 8.84 kCr |
| Rev. Growth (Yr) | 16.6% |
| Earnings (TTM) | 981.02 Cr |
| Earnings Growth (Yr) | -22.4% |
Profitability | |
|---|---|
| Operating Margin | 15% |
| EBT Margin | 14% |
| Return on Equity | 10.12% |
| Return on Assets | 6.53% |
| Free Cashflow Yield | 0.70% |
Cash Flow & Liquidity |
|---|
| Cash Flow from Investing (TTM) | -779.38 Cr |
| Cash Flow from Operations (TTM) | 1.42 kCr |
| Cash Flow from Financing (TTM) | -713.84 Cr |
| Cash & Equivalents | 101.17 Cr |
| Free Cash Flow (TTM) | 576.99 Cr |
| Free Cash Flow/Share (TTM) | 7.64 |
Balance Sheet | |
|---|---|
| Total Assets | 15.01 kCr |
| Total Liabilities | 5.32 kCr |
| Shareholder Equity | 9.69 kCr |
| Current Assets | 2.54 kCr |
| Current Liabilities | 1.72 kCr |
| Net PPE | 6.6 kCr |
| Inventory | 127.34 Cr |
| Goodwill | 4.53 kCr |
Capital Structure & Leverage | |
|---|---|
| Debt Ratio | 0.21 |
| Debt/Equity | 0.33 |
| Interest Coverage | 3.24 |
| Interest/Cashflow Ops | 7.51 |
Dividend & Shareholder Returns | |
|---|---|
| Dividend/Share (TTM) | 1 |
| Dividend Yield | 0.11% |
| Shares Dilution (1Y) | 0.00% |
| Shares Dilution (3Y) | 0.00% |
Growth: Good revenue growth. With 45.2% growth over past three years, the company is going strong.
Past Returns: Outperforming stock! In past three years, the stock has provided 50.5% return compared to 12.4% by NIFTY 50.
Smart Money: Smart money has been increasing their position in the stock.
Profitability: Recent profitability of 11% is a good sign.
Buy Backs: Company has bought back it's stock in the past which is a good thing.
Balance Sheet: Strong Balance Sheet.
Size: It is among the top 200 market size companies of india.
No major cons observed.
Growth: Good revenue growth. With 45.2% growth over past three years, the company is going strong.
Past Returns: Outperforming stock! In past three years, the stock has provided 50.5% return compared to 12.4% by NIFTY 50.
Smart Money: Smart money has been increasing their position in the stock.
Profitability: Recent profitability of 11% is a good sign.
Buy Backs: Company has bought back it's stock in the past which is a good thing.
Balance Sheet: Strong Balance Sheet.
Size: It is among the top 200 market size companies of india.
No major cons observed.
Investor Care | |
|---|---|
| Dividend Yield | 0.11% |
| Dividend/Share (TTM) | 1 |
| Shares Dilution (1Y) | 0.00% |
| Earnings/Share (TTM) | 12.72 |
Financial Health | |
|---|---|
| Current Ratio | 1.47 |
| Debt/Equity | 0.33 |
Technical Indicators | |
|---|---|
| RSI (14d) | 72.32 |
| RSI (5d) | 86.06 |
| RSI (21d) | 51.45 |
| MACD Signal | Buy |
| Stochastic Oscillator Signal | Sell |
| SharesGuru Signal | Buy |
| RSI Signal | Sell |
| RSI5 Signal | Sell |
| RSI21 Signal | Hold |
| SMA 5 Signal | Buy |
| SMA 10 Signal |
Updated May 5, 2025
The stock has returned -3.48% in the last day, reflecting recent market volatility.
Fortis Malar Hospitals has seen a decline of -6.36% over the past month.
Current trading showed volatility with a low of ₹74.76, indicating market uncertainty.
Summary of Fortis Healthcare's latest earnings call, featuring management's outlook on business performance, financial results, and analyst Q&A sessions that highlight key strategic initiatives and market challenges.
Fortis Healthcare Limited provided an optimistic outlook during its Q2 FY26 earnings call, highlighting strong growth in both hospital and diagnostics segments. The management reported consolidated revenues of INR 2,331 crores for Q2 FY26, reflecting a 17.3% increase year-on-year. The hospital revenues grew 19.3% to INR 1,974 crores, which constitutes 85% of total revenue, while diagnostics revenues increased by 7.1% to INR 357 crores.
Management reported consolidated operating EBITDA of INR 556 crores, up 28%, with a margin expansion from 21.9% to 23.9%. The profit after tax before exceptional items increased by 20.7% to INR 305 crores. For H1 FY26, total revenues reached INR 4,498 crores, representing a 16.9% growth, with hospital business revenue at INR 3,812 crores and an improvement of 250 basis points in operating margin to 22.5%.
Forward-looking points from management included plans for expansion and infrastructure growth, with a 15-year lease agreement for a 200-bed hospital in Greater Noida and operationalization of a new 550-bed super specialty hospital in Lucknow. The total operational beds increased by 550 in H1 FY26, with expectation to add approximately 400 to 500 beds annually going forward.
Improvement in hospital occupancy was also noted, increasing to 71%, along with a 5.8% growth in ARPOB, reaching INR 2.51 crores. International business contributed 8.1% to revenue, up from 7.7% in the previous year, with a focus on capitalizing on medical tourism.
Management anticipates maintaining this growth trajectory, with EBITDA margins potentially exceeding initial projections of 20.5% to 22.5% in the coming periods, driven by operational efficiencies and expanding capabilities.
Understand Fortis Healthcare ownership landscape with insights into key distribution patterns, offering investors a clear view of stakeholder dynamics.
| Shareholder Name | Holding % |
|---|---|
| NORTHERN TK VENTURE PTE. LTD. | 31.17% |
| HDFC MUTUAL FUND - HDFC PHARMA AND HEALTHCARE FUND | 5.96% |
| KOTAK AGGRESSIVE HYBRID FUND | 4.99% |
| AXIS ELSS TAX SAVER FUND | 3.12% |
| NIPPON LIFE INDIA TRUSTEE LTD-A/C NIPPON INDIA PHA | 2.37% |
| DSP ARBITRAGE FUND | 1.39% |
| FIDELITY FUNDS - INDIA FOCUS FUND |
Detailed comparison of Fortis Healthcare against industry peers, highlighting key financial metrics, valuation ratios, and performance indicators to provide competitive context within the sector.
Ticker | Name | Mkt Cap | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|---|
| APOLLOHOSP | Apollo Hospitals Enterprises | 1.1 LCr | 24.42 kCr | +5.30% | +21.50% | 60.78 | 4.48 | - | - |
| MAXHEALTH | Max Healthcare Institute |
Comprehensive comparison against sector averages
FORTIS metrics compared to Healthcare
| Category | FORTIS | Healthcare |
|---|---|---|
| PE | 72.07 | 61.82 |
| PS | 7.83 | 6.28 |
| Growth | 16 % | 16.9 % |
Fortis Healthcare is a prominent hospital company headquartered in Gurugram, India, recognized by the stock ticker FORTIS. The company boasts a substantial market capitalization of Rs. 50,974.8 Crores and has established itself as an integrated healthcare delivery service provider.
Offering a wide range of specialized services, Fortis Healthcare provides secondary, tertiary, and quaternary care across various medical fields. These include, but are not limited to:
The company's healthcare verticals also encompass hospitals, diagnostics, and day care specialty facilities.
Founded in 1995, Fortis Healthcare has shown remarkable financial growth, achieving a trailing 12-month revenue of Rs. 7,618.4 Crores and recording a profit of Rs. 824.5 Crores over the past four quarters. The company has experienced an impressive 35.5% revenue growth in the last three years.
In terms of shareholder returns, Fortis Healthcare offers a dividend yield of 0.15% per year, distributing Rs.1 dividend per share in the last 12 months, demonstrating its commitment to providing value to its investors.
This is an informational page just to provide a quick 'first look' at the stock. You must do your own deeper research. Know your risk appetite. Consult a SEBI-registered financial advisor before making any investment decisions.
| Buy |
| SMA 20 Signal | Buy |
| SMA 50 Signal | Buy |
| SMA 100 Signal | Buy |
FORTIS vs Healthcare (2021 - 2026)
High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 4 years
High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 4 years
Fortis Malar Hospitals has seen a significant gain of 29.63% over the last three months.
General • 16 Feb 2026 The relevant disclosure is attached. |
Analyst / Investor Meet • 16 Feb 2026 The relevant disclosure is attached. |
Newspaper Publication • 14 Feb 2026 The relevant disclosure is attached. |
Investor Presentation • 13 Feb 2026 The relevant disclosure is attached. |
Press Release / Media Release • 13 Feb 2026 The relevant disclosure is attached. |
General • 13 Feb 2026 The relevant disclosure is attached. |
This information is AI-generated and may contain inaccuracies. Please verify from multiple sources.
Question 1: "During the quarter, we had some extreme weather conditions in some parts of Northern India. Did any of the Fortis hospitals get impacted?"
Answer: Yes, our Ludhiana, Mohali, and Amritsar facilities were affected due to flooding in Punjab. However, we maintained normal operations despite a temporary decline in patient flow. Overall, our financial results remained satisfactory.
Question 2: "What is the expected impact on the P&L from the recent long-term lease agreement in Greater Noida?"
Answer: The rental P&L charge will be about INR2.3 crores per month, or INR27.6 crores annually. The unit currently generates INR10 crores in monthly revenue and operates at around 2-3% EBITDA margin.
Question 3: "What trajectory do you expect for the Diagnostics business margins going forward?"
Answer: We anticipate maintaining margins in the range of 23% to 24% for the full year, consistent with our H1 performance of around 24%.
Question 4: "Does the current O&M agreement with Gleneagles include Mumbai?"
Answer: No, the agreement does not cover Mumbai. However, we are exploring future opportunities to integrate their assets, including those in Hyderabad, into our operations.
Question 5: "What is the projected timeline for Noida hospital achieving mid-teen profitability?"
Answer: We expect to see EBITDA improvement to around 15% within about 6 months, which will entail some investment in medical equipment and enhancements.
Question 6: "Can you explain the factors behind the sharp improvement in operational leverage?"
Answer: The improvement is mainly due to operational efficiency gained from higher occupancy and better ramp-up of facilities. We expect this trend to continue as new capacities come online.
Question 7: "What is the current average realization per patient and average realization per test in Diagnostics?"
Answer: We have seen increases in both metrics mainly due to heightened focus on wellness packages, alongside the discontinuation of the lower-ticket Aam Aadmi Mohalla Clinics business.
Question 8: "What is the guidance for organic bed additions in FY27?"
Answer: We expect to add around 300 to 400 beds organically next fiscal year, focusing on additions from FMRI, Kolkata, and ramp-ups in Manesar and Bangalore.
Question 9: "What are your plans regarding debt reduction?"
Answer: We're comfortable with our current debt level, which is under 1x EBITDA. While we plan to reduce it over time, we also aim to leverage it for growth opportunities.
Question 10: "How does the CGHS impact your revenue mix?"
Answer: Our government payer contributions, including CGHS, generally represent 18% to 20% of our total revenue. We're anticipating positive effects from recent rate increases but are still evaluating specifics.
This summary captures the major questions and respective answers from the earnings call while keeping within the specified character limits.
| 1.35% |
| JUPITER INDIA FUND | 1.26% |
| AXIS BANK LIMITED | 1.19% |
| KOTAK FUNDS - INDIA MIDCAP FUND | 1.17% |
| EDELWEISS TRUSTEESHIP CO LTD AC- EDELWEISS MF AC- | 1.11% |
Distribution across major stakeholders
Distribution across major institutional holders
| 1.05 LCr |
| 8.3 kCr |
| +3.80% |
| +7.20% |
| 73.69 |
| 12.61 |
| - |
| - |
| NH | Narayana Hrudayalaya | 37.54 kCr | 6.88 kCr | -4.20% | +38.30% | 47.9 | 5.46 | - | - |
| ASTERDM | Aster DM Healthcare | 32.16 kCr | 4.58 kCr | +3.50% | +49.40% | 96.83 | 7.02 | - | - |
| MEDANTA | Global Health | 30.78 kCr | 4.27 kCr | +0.10% | +3.10% | 59.89 | 7.21 | - | - |
| KIMS | Krishna Institute of Medical Sciences | 27.39 kCr | 3.65 kCr | +11.40% | +17.70% | 91.25 | 7.51 | - | - |
| HCG | HealthCare Global Enterprises | 8.24 kCr | 2.5 kCr | -9.50% | +19.40% | 432.93 | 3.3 | - | - |
| -22.7% |
| 308 |
| 398 |
| 335 |
| 285 |
| 254 |
| 317 |
| Exceptional items before tax | -304% | -45.91 | 24 | 13 | -53.57 | 24 | -59.77 |
| Total profit before tax | -38% | 262 | 422 | 348 | 232 | 277 | 257 |
| Current tax | 14.9% | 55 | 48 | 40 | 34 | 45 | 52 |
| Deferred tax | -75% | 13 | 49 | 44 | 14 | -19.56 | 16 |
| Total tax | -30.2% | 68 | 97 | 84 | 49 | 25 | 68 |
| Total profit (loss) for period | -40.2% | 197 | 329 | 267 | 188 | 254 | 193 |
| Other comp. income net of taxes | -33.8% | 4.48 | 6.26 | -0.45 | -3.04 | 0.45 | -0.6 |
| Total Comprehensive Income | -39.8% | 202 | 335 | 266 | 185 | 255 | 192 |
| Earnings Per Share, Basic | -51.8% | 2.57 | 4.26 | 3.45 | 2.44 | 3.28 | 2.34 |
| Earnings Per Share, Diluted | -51.8% | 2.57 | 4.26 | 3.45 | 2.44 | 3.28 | 2.34 |
| Debt equity ratio | 0% | 035 | 033 | 028 | 027 | 0 | - |
| Debt service coverage ratio | 0.1% | 0.0177 | 0.0168 | 0.0592 | 0.0849 | 0.03 | - |
| Interest service coverage ratio | -1.9% | 0.0604 | 0.0778 | 0.0732 | 0.0681 | 0.09 | - |
| 10.2% |
| 207 |
| 188 |
| 175 |
| 154 |
| 148 |
| 155 |
| Finance costs | 37% | 112 | 82 | 106 | 130 | 141 | 160 |
| Depreciation and Amortization | 12% | 113 | 101 | 116 | 113 | 111 | 97 |
| Other expenses | 23.1% | 603 | 490 | 479 | 389 | 307 | 331 |
| Total Expenses | 20.8% | 1,415 | 1,172 | 1,142 | 989 | 857 | 891 |
| Profit Before exceptional items and Tax | 50.7% | 230 | 153 | 61 | 7.29 | -32.33 | 749 |
| Exceptional items before tax | -224.9% | -115.14 | 94 | 48 | -16.28 | 56 | -128.63 |
| Total profit before tax | -54.1% | 114 | 247 | 109 | -8.99 | 24 | 621 |
| Current tax | 7.4% | 30 | 28 | 8.78 | 2.3 | 13 | 112 |
| Deferred tax | 5.6% | 20 | 19 | 3.86 | 1.96 | 7.22 | -4.73 |
| Total tax | 8.7% | 51 | 47 | 13 | 4.26 | 20 | 107 |
| Total profit (loss) for period | -68.2% | 64 | 199 | 96 | -13.25 | 4.2 | 513 |
| Other comp. income net of taxes | -84.2% | -1.45 | -0.33 | -1.27 | 0.28 | 0.86 | -0.12 |
| Total Comprehensive Income | -69.2% | 62 | 199 | 95 | -12.97 | 5.06 | 513 |
| Earnings Per Share, Basic | -109.8% | 0.84 | 2.64 | 1.27 | -0.18 | 0.06 | 6.8 |
| Earnings Per Share, Diluted | -109.8% | 0.84 | 2.64 | 1.27 | -0.18 | 0.06 | 6.8 |
| Debt equity ratio | - | 022 | - | - | - | - | - |
| Debt service coverage ratio | - | 0.0205 | - | - | - | - | - |
| Interest service coverage ratio | - | 0.0407 | - | - | - | - | - |
| 31.7% |
| 55 |
| 42 |
| 119 |
| 259 |
| 280 |
| 2.67 |
| Goodwill | 0% | 27 | 27 | 27 | 27 | 27 | 27 |
| Non-current investments | -0.7% | 10,110 | 10,178 | 8,754 | 8,834 | 8,773 | 8,848 |
| Loans, non-current | 6.2% | 18 | 17 | 18 | 16 | 162 | 146 |
| Total non-current financial assets | -0.7% | 10,129 | 10,196 | 8,773 | 8,851 | 8,937 | 8,995 |
| Total non-current assets | -0.2% | 11,489 | 11,516 | 9,594 | 9,620 | 9,837 | 9,549 |
| Total assets | -0.1% | 11,985 | 11,999 | 10,388 | 10,387 | 10,335 | 10,369 |
| Borrowings, non-current | -0.8% | 1,885 | 1,901 | 401 | 514 | 580 | 625 |
| Total non-current financial liabilities | -0.8% | 1,885 | 1,901 | 401 | 514 | 580 | 627 |
| Provisions, non-current | 25% | 36 | 29 | 29 | 26 | 25 | 22 |
| Total non-current liabilities | -0.4% | 1,922 | 1,930 | 430 | 540 | 605 | 648 |
| Borrowings, current | 4.4% | 144 | 138 | 181 | 145 | 153 | 160 |
| Total current financial liabilities | -10.4% | 840 | 937 | 842 | 713 | 695 | 602 |
| Provisions, current | -4.2% | 24 | 25 | 22 | 22 | 22 | 22 |
| Current tax liabilities | - | 0 | 0 | 0 | 0 | 0 | 0 |
| Total current liabilities | -10.8% | 888 | 995 | 881 | 760 | 734 | 645 |
| Total liabilities | -3.9% | 2,810 | 2,925 | 1,311 | 1,300 | 1,339 | 1,405 |
| Equity share capital | 0% | 755 | 755 | 755 | 755 | 755 | 755 |
| Total equity | 1.1% | 9,175 | 9,074 | 9,077 | 9,087 | 8,996 | 8,964 |
| Total equity and liabilities | -0.1% | 11,985 | 11,999 | 10,388 | 10,387 | 10,335 | 10,369 |
| - |
| -2.03 |
| 0 |
| 34 |
| 49 |
| - |
| - |
| Other inflows (outflows) of cash | - | 0 | 0 | 0 | 14 | - | - |
| Net Cashflows From Operating Activities | 38.2% | 334 | 242 | 198 | 76 | - | - |
| Cashflows used in obtaining control of subsidiaries | -102.1% | 0 | 48 | 0 | 0.02 | - | - |
| Proceeds from sales of PPE | -100.4% | 0.34 | 150 | 0.15 | 0.18 | - | - |
| Purchase of property, plant and equipment | 12.3% | 365 | 325 | 54 | 27 | - | - |
| Cash receipts from repayment of advances and loans made to other parties | 11638.5% | 76 | 0.35 | 100 | 123 | - | - |
| Dividends received | 475% | 70 | 13 | 21 | 0 | - | - |
| Interest received | 31% | 284 | 217 | 91 | 141 | - | - |
| Other inflows (outflows) of cash | 197.9% | 99 | -99.06 | 46 | 1.11 | - | - |
| Net Cashflows From Investing Activities | -3758.6% | -1,572.21 | 44 | 205 | 238 | - | - |
| Proceeds from issuing debt | - | 1,550 | 0 | 0 | 0 | - | - |
| Proceeds from borrowings | -99.6% | 1.96 | 241 | 54 | 218 | - | - |
| Repayments of borrowings | -73.3% | 80 | 297 | 319 | 359 | - | - |
| Payments of lease liabilities | - | 48 | 0 | 24 | 49 | - | - |
| Dividends paid | 0% | 75 | 75 | 0 | 0 | - | - |
| Interest paid | -11.1% | 73 | 82 | 106 | 129 | - | - |
| Income taxes paid (refund) | -104.5% | 0 | 23 | 0 | 0 | - | - |
| Net Cashflows from Financing Activities | 573.2% | 1,276 | -268.42 | -395.44 | -319.82 | - | - |
| Net change in cash and cash eq. | 117.6% | 38 | 18 | 7.59 | -5.59 | - | - |
Analyst / Investor Meet • 06 Feb 2026 The relevant disclosure is attached. |
Analysis of Fortis Healthcare's financial performance, highlighting revenue trends, growth patterns, and key metrics through quarterly analysis.
Last Updated: Dec 31, 2025
| Description | Share | Value |
|---|---|---|
| Healthcare | 83.9% | 1.9 kCr |
| Diagnostic | 16.1% | 370.9 Cr |
| Total | 2.3 kCr |